The RSA Group Recruits CEO for Clasado BioSciences
May 2, 2019 – Persistent talent shortages and the need to develop and retain employees with critical business and technology skill-sets will continue to challenge global life sciences companies for the foreseeable future, according to Deloitte’s global sector outlook on life sciences.
Navigating this new world of work requires a dramatic change in strategies for leadership, talent and human resources. What’s more, the global life sciences sector in the midst of a turbulent transformation, making the need for innovative leaders more important than ever.
The RSA Group, which is based in London and focuses on the life sciences sector, recently placed Per Rehné as CEO at Clasado BioSciences, a provider of gut mediated wellness solutions./
“Per’s appointment followed an extensive global search and careful candidate due diligence by our team,” said Paul Foster, senior consultant at the RSA Group. “Our long-term relationship with Clasado gave us the insights that we needed to find the best CEO for the role.”
“RSA’s ability to access and engage the best candidates was critical to the success of this search and to its completion within our timeframe,” said Moncef Slaoui, chairman of Clasado. “The candidates on the final shortlist were all of high quality which made for a competitive final selection.”
Mr. Rehné has worked in senior positions at many leading health and nutrition companies over the last 20 years, including Danisco, Frutarom, Cornelius and OptiBiotix, where he remains a non-executive director of the ProBiotix Business Division.
“Per has an enviable track record in delivering strategic growth and we are delighted he agreed to head up our team,” said Mr. Slaoui. “We are excited about the potential he sees for our products and innovation pipeline.”
“I’m pleased to be joining Clasado at a key time in the company’s history,” said Mr. Rehné. “With more than 15 years of scientific research and experience in the development of its global IP position for gut wellness solutions, and the increasing growth in focus on health and well-being by consumers, the future looks bright for the company.”
Closing the Deal with Candidates in the Life Sciences Sector
The competitive landscape of the life sciences industry is transforming recruiting. “Growing pressure to rapidly advance scientific discovery and expand market share is making the competition to attract top talent as fierce as ever,” according to a report by Dan Strauss, head of the pharmacovigilance and risk management practice at Klein Hersh International.
Clasado BioSciences researches and develops the world’s most advanced galacto-oligosaccharide (GOS) products, providing solutions for food, healthcare and pharmaceutical companies across the global wellness market.
Life Sciences Recruiters
The RSA Group advises on the selection, assessment and onboarding of board and senior executive talent for the life sciences. Specializing in C-suite, senior executive and board level searches, its clients include global industry leaders through to start-up businesses. RSA Group operates in pharmaceuticals, biotechnology, medical devices, diagnostics, generics, consumer healthcare, animal health, service organizations, venture capital, charities and academic medical research. Established in 1981, the firm has offices in the U.S., U.K., Germany, Switzerland, Turkey, Singapore and China.
With over 35 years of experience in the biopharmaceutical industry and executive search, Mr. Foster specializes in both executive search and executive interims. Through his years in executive search, he has created a number of successful search practices and has developed a deep understanding of commercial, clinical development, medical and regulatory affairs, and the specific needs of both clients and candidates. His broad life sciences expertise covers pharma, biotech, medical devices and diagnostics, clinical development, rare diseases and orphan drugs. Mr. Foster’s current focus is on venture capital backed start-ups with a special interest in in gene and cell therapy, and executive level regulatory roles.
Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; Stephen Sawicki, Managing Editor; and Andrew W. Mitchell, Managing Editor – Hunt Scanlon Media
